Nuvation Bio is trading 4.2% down at $5.50, with broader macro sentiment the likeliest context rather than a confirmed company-driven move.
- No new company-specific catalyst was identified in available company news; the investor newsroom’s latest listed announcement is dated September 21, 2026.
- Markets turned risk-off after rejection of the Iran proposal; rising oil prices and elevated Treasury yields added pressure, while major indexes were also lower.